Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Minerva Biotechnologies Announces Major Stem Cell Breakthrough

Abstract:
Minerva Biotechnologies, a leading nanotechnology, cancer and stem cell development company today announced a major breakthrough in stem cell research. Minerva and collaborators at the University of California at Santa Barbara discovered that a single, new growth factor can not only support massive growth of human embryonic stem cells (hESCs) in vitro, but also maintains them in a nearly 100% undifferentiated state without the need for fibroblast "feeder cells". This represents a major step forward for potential stem cell therapies as well as in the basic understanding of the mechanisms that regulate stem cell growth and differentiation.

Minerva Biotechnologies Announces Major Stem Cell Breakthrough

Boston, MA | Posted on October 4th, 2008

Their study, "MUC1* Mediates the Growth of Human Pluripotent Stem Cells"
(dx.plos.org/10.1371/journal.pone.0003312), will be published tomorrow, October 3, 2008, in the journal PLoS ONE. The bi-coastal research team, led by Minerva's Chief Scientific Officer Dr. Cynthia Bamdad, discovered that a cell surface protein, MUC1, is in an altered form, MUC1*, on pluripotent embryonic stem cells but returns to its normal form when the stem cells begin to differentiate. This suggests that this receptor may be a pivotal switch in the process of differentiation. The investigators showed that by adding the growth factor that binds to MUC1* they could expand the hESCs and maintain pluripotency essentially indefinitely, yet commence differentiation upon removal of the factor. Kenneth S. Kosik, M.D., the Harriman Professor of Neuroscience and Co-Director of the UC Santa Barbara Neuroscience Research Institute, as well as a co-author on the paper said, "Given the extreme difficulty of isolating pure primitive human stem cells and amplifying them, these studies represent a big step forward for human stem cell research and the future of stem cell transplantation."

Remarkably, in a research article that published earlier this year, "A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells", PLoS ONE 3(4): e2054 doi:10.1371/journal.pone.0002054), Minerva reported that MUC1 exists in the same altered form, MUC1*, on over 75% of human cancers. An emerging theory in cancer research is that cancer may be caused by a stem cell mechanism that has gone awry. Until now, parallels between stem cell growth and cancer growth have largely been speculative. The present study provides evidence of a fundamental growth mechanism that mediates the growth of both cancer cells and embryonic stem cells. The hunt for a stem cell mechanism that is "hijacked by cancer cells" was a challenge because it involved a molecular change that was only apparent when "viewed" using Minerva's proprietary nanoparticles.

####

About Minerva Biotechnologies
Minerva is a US-headquartered company focused on a next generation novel nanoparticle platform. Minerva enjoys a broad and dominant intellectual property position in the field of nanotechnology with over 100 patents or patent applications filed with US and worldwide rights reserved. Minerva’s intellectual property covers a wide range of uses for its nanoparticle systems in fields as diverse as drug discovery, proteomics, opto-electronics and nano-scale biosensors. Minerva has focused squarely on drug discovery and diagnostics for cancer and stem cell treatments and has used its nanotechnology in-house to expedite novel target identification and new drug development.

Copyright © 2008, Minerva Biotechnologies. All rights reserved.

For more information, please click here

Contacts:
Minerva Biotechnologies
Cynthia Bamdad
617-821-8773

Copyright © Minerva Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Discoveries

ANU invention to inspire new night-vision specs December 7th, 2016

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Announcements

ANU invention to inspire new night-vision specs December 7th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Research partnerships

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Novel silicon etching technique crafts 3-D gradient refractive index micro-optics November 28th, 2016

Single photon converter -- a key component of quantum internet November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project